Tharimmune, Inc. - Common Stock (THAR)

Shares of Tharimmune are surging Thursday afternoon. The company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Thursday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

U.S. stock futures were slightly below the flatline on Thursday following Wednesday's mixed close. Futures were lower.

Tharimmune soared over 42% after hours Wednesday after reporting strong data for its opioid overdose prevention drug.

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.